Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 3/2011

01-06-2011

Bone Health Issues in Sarcoidosis

Authors: Nadera J. Sweiss, Elyse E. Lower, Peter Korsten, Timothy B. Niewold, Murray J. Favus, Robert P. Baughman

Published in: Current Rheumatology Reports | Issue 3/2011

Login to get access

Abstract

Sarcoidosis affects the bone directly in only a minority of patients. Nonetheless, bone health should be considered in the management of all patients with sarcoidosis. Deficiency in vitamin D, an important contributor to bone health, has been linked to autoimmune disease incidence. Studies have shown that patients with sarcoidosis frequently have low levels of vitamin D-25 but may have normal or increased levels of vitamin D-1,25. In addition, granuloma formation has been linked to a failure of the innate immune system, which could be related to a deficiency in vitamin D, although this relationship has not been fully characterized. Furthermore, many patients with sarcoidosis are treated with corticosteroids, which are known to induce osteoporosis. Therefore, bone health may be impacted in several ways in sarcoidosis—by direct involvement with granulomas, vitamin D deficiency, or corticosteroid therapy.
Literature
1.
2.
Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax. 1998;53:425–9.PubMedCrossRef
3.
• Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med. 2010;31:474–84. This is a great review about the nuances of managing calcium and vitamin D levels in sarcoidosis. Because it specifically focuses on sarcoidosis, it may serve as a roadmap to the supportive care that is required by these patients.PubMedCrossRef
4.
• Richmond BW, Drake WP. Vitamin D, innate immunity, and sarcoidosis granulomatous inflammation: insights from mycobacterial research. Curr Opin Pulm Med. 2010;16:461–4. This intriguing and potentially controversial study has raised the question of whether vitamin D supplementation may not be helpful in treating sarcoidosis.PubMedCrossRef
5.
Chatham W. Rheumatic manifestations of systemic disease: sarcoidosis. Curr Opin Rheumatol. 2010;22:85–90.PubMedCrossRef
6.
Ugwonali OF, Parisien M, Nickerson KG, Scully B, Ristic S, et al. Osseous sarcoidosis of the hand: pathologic analysis and review of the literature. J Hand Surg Am. 2005;30:854–8.PubMedCrossRef
7.
Shorr AF, Murphy FT, Kelly WF, Kaplan KJ, Gilliland WR, et al. Osseous Sarcoidosis Clinical, Radiographic, and Therapeutic Observations. J Clin Rheumatol. 1998;4:186–92.PubMedCrossRef
8.
Ly JQ. An unusual cause of knee pain: a rare case of osseous sarcoid (2003:5b). Eur Radiol. 2003;13:2055–7.PubMedCrossRef
9.
Rua-Figueroa I, Gantes MA, Erausquin C, Mhaidli H, Montesdeoca A. Vertebral sarcoidosis: clinical and imaging findings. Semin Arthritis Rheum. 2002;31:346–52.PubMedCrossRef
10.
Poyanli A, Poyanli O, Sencer S, Akan K, Sayrak H, et al. Vertebral sarcoidosis: imaging findings. Eur Radiol. 2000;10:92–4.PubMedCrossRef
11.
Binicier O, Sari I, Sen G, Onen F, Akkoc N, et al. Axial sarcoidosis mimicking radiographic sacroiliitis. Rheumatol Int. 2009;29:343–5.PubMedCrossRef
12.
Lisle D, Mitchell K, Crouch M, Windsor M. Sarcoidosis of the thoracic and lumbar spine: imaging findings with an emphasis on magnetic resonance imaging. Australas Radiol. 2004;48:404–7.PubMedCrossRef
13.
Mangino D, Stover DE. Sarcoidosis presenting as metastatic bony disease. A case report and review of the literature on vertebral body sarcoidosis. Respiration. 2004;71:292–4.PubMedCrossRef
14.
15.
Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med. 2009;122:793–802.PubMedCrossRef
16.
17.
18.
Nam HS, Shin MH, Zmuda JM, Leung PC, Barrett-Connor E, et al. Race/ethnic differences in bone mineral densities in older men. Osteoporos Int. 2010;21:2115–23.PubMedCrossRef
19.
Mason RS, Frankel T, Chan YL, Lissner D, Posen S. Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med. 1984;100:59–61.PubMed
20.
Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1, 25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med. 1989;111:437–8.PubMed
21.
Hamada K, Nagai S, Tsutsumi T, Izumi T. Ionized calcium and 1, 25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J. 1998;11:1015–20.PubMedCrossRef
22.
• Kavathia D, Buckley JD, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med. 2010;104:564–70. This study has defined a relationship between elevated Vit D-1,25 and chronic sarcoidosis, thus adding further evidence of the role of vitamin D in this autoimmune disorder.PubMedCrossRef
23.
Ben-Zvi I, Aranow C, Mackay M, Stanevsky A, Kamen DL, et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS ONE. 2010;5:e9193.PubMedCrossRef
24.
Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492–502.PubMedCrossRef
25.
Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:948364.PubMedCrossRef
26.
Kariuki SN, Franek BS, Kumar AA, Arrington J, Mikolaitis RA, et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R151.PubMedCrossRef
27.
Reichel H, Koeffler HP, Tobler A, Norman AW. 1 alpha, 25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA. 1987;84:3385–9.PubMedCrossRef
28.
Stoffels K, Overbergh L, Giulietti A, Verlinden L, Bouillon R, et al. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res. 2006;21:37–47.PubMedCrossRef
29.
Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.PubMedCrossRef
30.
Swaisgood CM, Oswald-Richter K, Moeller SD, Klemenc JM, Ruple LM, et al. Development of a sarcoidosis murine lung granuloma model using mycobacterium sodA. Am J Respir Cell Mol Biol. 2010;26:26.
31.
Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res Hoboken. 2010;62:1515–26.PubMedCrossRef
32.
Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, et al. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Int. 1990;5:164–8.PubMed
33.
Rizzato G, Tosi G, Mella C, Montemurro L, Zanni D, et al. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis. 1988;5:93–8.PubMed
34.
Sweiss NJ, Patterson K, Sawaqed R, Jabbar U, Korsten P, et al. Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med. 2010;31:463–73.PubMedCrossRef
35.
• Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature. 2010;465:937–41. This thought-provoking and somewhat controversial report has provided a potential explanation for the differential efficacy of corticosteroids in treatment of SLE.PubMedCrossRef
36.
Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.PubMedCrossRef
37.
Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2006;25:596–7.PubMedCrossRef
38.
Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27:49–56.PubMed
39.
Garg S, Garg K, Altaf M, Magaldi JA. Refractory vertebral sarcoidosis responding to infliximab. J Clin Rheumatol. 2008;14:238–40.PubMedCrossRef
40.
Agrawal S, Bhagat S, Dasgupta B. Sarcoid sacroiliitis: successful treatment with infliximab. Ann Rheum Dis. 2009;68:283.PubMedCrossRef
41.
Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72:337–40.PubMedCrossRef
42.
Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:201–8.PubMed
43.
Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum. 2003;48:3542–3.PubMedCrossRef
44.
Sweiss NJ, Noth IN, Baughman RP, Curran J, Naureckas E, et al. 52-Week Trial Results of Adalimumab as Novel Therapy for Refractory, Progressive Pulmonary Sarcoidosis. American Thoracic Society 2010 International Conference; New Orleans, LA Abstract A2370. 2010.
45.
Menon Y, Cucurull E, Reisin E, Espinoza LR. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci. 2004;328:173–5.PubMedCrossRef
46.
Ishibashi K, Kodama M, Hanada S, Arima T. Tumor necrosis factor-beta and hypercalcemia. Leuk Lymphoma. 1992;7:409–17.PubMedCrossRef
47.
Mundy GR. Incidence and pathophysiology of hypercalcemia. Calcif Tissue Int. 1990;46(Suppl):S3–10.PubMedCrossRef
48.
Bachwich PR, Lynch 3rd JP, Larrick J, Spengler M, Kunkel SL. Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol. 1986;125:421–5.PubMed
49.
Adams JS, Sharma OP, Diz MM, Endres DB. Ketoconazole decreases the serum 1, 25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab. 1990;70:1090–5.PubMedCrossRef
50.
Rizzato G, Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13:167–72.PubMed
51.
Dawson-Hughes B. A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab. 2008;93:2463–5.PubMedCrossRef
52.
Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum. 2010;8:8.
53.
Arai T, Inoue Y, Hayashi S, Yamamoto S, Sakatani M. Risedronate induced BOOP complicated with sarcoidosis. Thorax. 2005;60:613–4.PubMedCrossRef
54.
Rolla G, Bucca C, Brussino L. Bisphosphonate-induced bronchoconstriction in aspirin-sensitive asthma. Lancet. 1994;343:426–7.PubMedCrossRef
55.
Pena de la Vega L, Fervenza FC, Lager D, Habermann T, Leung N. Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium. Ren Fail. 2005;27:485–9.PubMedCrossRef
56.
Buysschaert M, Cosyns JP, Barreto L, Jadoul M. Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant. 2003;18:826–9.PubMedCrossRef
57.
Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, et al. Pamidronate-induced nephrotoxic tubular necrosis—a case report. Clin Nephrol. 2004;61:63–7.PubMed
58.
Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997;61:386–92.PubMedCrossRef
Metadata
Title
Bone Health Issues in Sarcoidosis
Authors
Nadera J. Sweiss
Elyse E. Lower
Peter Korsten
Timothy B. Niewold
Murray J. Favus
Robert P. Baughman
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 3/2011
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-011-0170-1

Other articles of this Issue 3/2011

Current Rheumatology Reports 3/2011 Go to the issue

ReviewPaper

New Imaging Modalities in Bone

ReviewPaper

Mechanisms of Action of Intravenous Immunoglobulin in Inflammatory Muscle Disease

ReviewPaper

Juvenile Dermatomyositis

ReviewPaper

High-Dose Vitamin D: Helpful or Harmful?

ReviewPaper

Mechanical Means to Improve Bone Strength: Ultrasound and Vibration

ReviewPaper

Advances in Glucocorticoid-Induced Osteoporosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits